Annals of African medicine · 2026
Systematic Review and Meta-analysis on the Prevalence of Common Hemoglobinopathies in India.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Das Soumyajit, Ghai Glory, Sathianath Shruthy, Savitha S, Sumathi S, Joseph Felista Karen, Satapathy Prakasini, Gandhi Aravind P
Аннотация
CONTEXT: In India, hemoglobinopathies such as beta-thalassemia, sickle cell disease, and glucose-6-phosphate dehydrogenase (G6PD) deficiency are major public health concerns.
AIMS: The present meta-analysis aimed to aggregate data on the prevalence and distribution of these nationally significant hemoglobinopathies across various demographic segments of India.
MATERIALS AND METHODS: The systematic review adhered to PRISMA 2020 guidelines. Four databases - Web of Science, PubMed, ProQuest, and Embase - were searched till 12.05.2024. Risk of bias assessment studies were undertaken using the JBI Critical Appraisal Checklist.
STATISTICAL ANALYSIS USED: Pooled estimate of prevalence of each hemoglobinopathies and their traits was calculated with 95% confidence interval (CI). I2 statistics and the prediction interval were calculated to depict the heterogeneity. All statistical analyses were done in R studio.
RESULTS: Database search yielded 1418 articles, among which 99 studies were finally included. Pooled prevalence of sickle cell anemia from 656,005 participants was 2% (95% CI: 1%-3%, I2 = 99.6%). Pooled prevalence of sickle cell trait was 5% (95% CI: 2%-8%, I2 = 99.9%). Pooled prevalence of beta thalassemia was 6% (95% CI: 2%-12%, I2 = 99.9%). Pooled prevalence of beta thalassemia trait was 7% (95% CI: 4%-9%, I2 = 99.6%). Pooled prevalence of G6PD deficiency was 5% (95% CI: 3%-8%, I2 = 98.8%). Subgroup analysis revealed varying prevalence of hemoglobinopathies across the regions and states.
CONCLUSIONS: The study findings highlight the burden and subsequent need for region-specific (decentralized) strategies for managing hemoglobinopathies. Addressing the burden through early diagnosis, genetic counseling, and public health interventions is crucial in reducing morbidity and improving health outcomes.
AIMS: The present meta-analysis aimed to aggregate data on the prevalence and distribution of these nationally significant hemoglobinopathies across various demographic segments of India.
MATERIALS AND METHODS: The systematic review adhered to PRISMA 2020 guidelines. Four databases - Web of Science, PubMed, ProQuest, and Embase - were searched till 12.05.2024. Risk of bias assessment studies were undertaken using the JBI Critical Appraisal Checklist.
STATISTICAL ANALYSIS USED: Pooled estimate of prevalence of each hemoglobinopathies and their traits was calculated with 95% confidence interval (CI). I2 statistics and the prediction interval were calculated to depict the heterogeneity. All statistical analyses were done in R studio.
RESULTS: Database search yielded 1418 articles, among which 99 studies were finally included. Pooled prevalence of sickle cell anemia from 656,005 participants was 2% (95% CI: 1%-3%, I2 = 99.6%). Pooled prevalence of sickle cell trait was 5% (95% CI: 2%-8%, I2 = 99.9%). Pooled prevalence of beta thalassemia was 6% (95% CI: 2%-12%, I2 = 99.9%). Pooled prevalence of beta thalassemia trait was 7% (95% CI: 4%-9%, I2 = 99.6%). Pooled prevalence of G6PD deficiency was 5% (95% CI: 3%-8%, I2 = 98.8%). Subgroup analysis revealed varying prevalence of hemoglobinopathies across the regions and states.
CONCLUSIONS: The study findings highlight the burden and subsequent need for region-specific (decentralized) strategies for managing hemoglobinopathies. Addressing the burden through early diagnosis, genetic counseling, and public health interventions is crucial in reducing morbidity and improving health outcomes.